Status:
TERMINATED
Spectral Analysis Probe to Identify Glioblastoma Cells
Lead Sponsor:
University of Oklahoma
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a pilot, observational study to evaluate the intraoperative sensitivity of the Chaos Wand in detecting tumor tissue with glioblastoma disease.
Detailed Description
This is a pilot study to investigate if the Chaos Wand Spectral Diagnosis Probe can be used to identify Glioblastoma (GBM) cancer cells in patients undergoing standard surgical resection. Eligible pat...
Eligibility Criteria
Inclusion
- Male or Female and over 18 years of age.
- Patients with histologically proven GBM who are newly diagnosed and eligible to undergo surgical treatment or patients who are suspected of having glioblastoma on pre-operative imaging which is subsequently confirmed by histopathology following tumor resection.
- Patients must be able to understand and willing to sign the informed consent document.
Exclusion
- Patients with absence of glioblastoma.
- Patients who are not undergoing tumor resection.
- Patients who have prior brain radiotherapy
- Patients who have prior systemic chemotherapy
- Patients who are not willing to sign the informed consent and agree to participate.
- Patients who are pregnant or nursing
Key Trial Info
Start Date :
October 31 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2018
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03293888
Start Date
October 31 2017
End Date
September 30 2018
Last Update
January 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104